leflunomide has been researched along with Cytomegalovirus Retinitis in 4 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Cytomegalovirus Retinitis: Infection of the retina by cytomegalovirus characterized by retinal necrosis, hemorrhage, vessel sheathing, and retinal edema. Cytomegalovirus retinitis is a major opportunistic infection in AIDS patients and can cause blindness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To describe leflunomide use in the treatment of drug resistant cytomegalovirus retinitis." | 7.85 | Utility of Leflunomide in the Treatment of Drug Resistant Cytomegalovirus Retinitis. ( Goldstein, DA; Jumroendararasame, C; Minkus, CL; Pursell, K; Rifkin, LM, 2017) |
| "Leflunomide is a novel drug with both immunosuppressive and anti-CMV properties." | 5.33 | Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. ( Chan, LK; Levi, ME; Mandava, N; Olson, JL; Weinberg, A, 2006) |
| "To describe leflunomide use in the treatment of drug resistant cytomegalovirus retinitis." | 3.85 | Utility of Leflunomide in the Treatment of Drug Resistant Cytomegalovirus Retinitis. ( Goldstein, DA; Jumroendararasame, C; Minkus, CL; Pursell, K; Rifkin, LM, 2017) |
| "Leflunomide is a novel drug with both immunosuppressive and anti-CMV properties." | 1.33 | Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. ( Chan, LK; Levi, ME; Mandava, N; Olson, JL; Weinberg, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, L | 1 |
| Santhanakrishnan, K | 1 |
| Al-Aloul, M | 1 |
| Jones, NP | 1 |
| Steeples, LR | 1 |
| Dunn, JH | 1 |
| Weinberg, A | 2 |
| Chan, LK | 2 |
| Mandava, N | 2 |
| Levi, ME | 2 |
| Olson, JL | 2 |
| Rifkin, LM | 1 |
| Minkus, CL | 1 |
| Pursell, K | 1 |
| Jumroendararasame, C | 1 |
| Goldstein, DA | 1 |
1 review available for leflunomide and Cytomegalovirus Retinitis
| Article | Year |
|---|---|
Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches.
Topics: Antiviral Agents; Cytomegalovirus Retinitis; Drug Resistance, Viral; Foscarnet; Ganciclovir; Humans; | 2020 |
3 other studies available for leflunomide and Cytomegalovirus Retinitis
| Article | Year |
|---|---|
Long-term suppression of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide.
Topics: Administration, Oral; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Retinitis; Drug Resi | 2013 |
Utility of Leflunomide in the Treatment of Drug Resistant Cytomegalovirus Retinitis.
Topics: Administration, Oral; Aged; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Retinitis; Drug Resis | 2017 |
Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide.
Topics: Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Retinitis; Drug Resistance, Multiple, Vira | 2006 |